Want to see TSE:RAMM full AI Analyst Report?
Top Page
Ramm Pharma
(RAMM)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.01
▲(0.00% Upside)
Action:Upgraded
Date:10/03/26
The score is held down primarily by weak financial performance (shrinking revenue, ongoing losses, and persistent cash burn with equity erosion). Technicals also remain bearish with negative momentum and the price below key long-term moving averages, while valuation provides little support due to negative earnings and no stated dividend yield.
Positive Factors
Low leverage
Very low debt relative to equity limits refinancing and balance-sheet stress, preserving flexibility while the company works through losses. This is a meaningful stabilizer over the next several quarters, even though it does not offset weak operating performance.
Negative Factors
Sharp revenue decline
TTM revenue declined 32.9%, showing weakening demand or traction relative to prior periods. A shrinking sales base makes it harder to absorb operating costs, reach break-even, and finance growth internally, leaving recovery dependent on restoring revenue momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Very low debt relative to equity limits refinancing and balance-sheet stress, preserving flexibility while the company works through losses. This is a meaningful stabilizer over the next several quarters, even though it does not offset weak operating performance.
Read all positive factors
Ramm Pharma (RAMM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.19M
Dividend YieldN/A
Average Volume (3M)10.90K
Price to Earnings (P/E)―
Beta (1Y)-3.60
Revenue Growth-66.40%
EPS Growth31.38%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.08
Shares Outstanding119,389,320
10 Day Avg. Volume17,400
30 Day Avg. Volume10,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ramm Pharma Business Overview & Revenue Model
Company Description
RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other ...
Ramm Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jan 2026 | Jan 2025 | Jan 2024 | Jan 2023 | Jan 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.27M | 3.36M | 4.34M | 5.07M | 3.90M | 4.12M |
| Gross Profit | -59.57K | 373.93K | 1.76M | 381.82K | 530.50K | -7.64K |
| EBITDA | -3.67M | -3.78M | -15.23M | -6.30M | -19.91M | -6.36M |
| Net Income | -9.08M | -8.91M | -16.50M | -7.72M | -20.96M | -7.11M |
Balance Sheet | ||||||
| Total Assets | 6.72M | 9.27M | 16.75M | 32.30M | 39.31M | 59.71M |
| Cash, Cash Equivalents and Short-Term Investments | 147.13K | 803.88K | 814.04K | 5.12M | 9.77M | 17.16M |
| Total Debt | 169.55K | 80.39K | 188.31K | 405.14K | 683.70K | 32.16K |
| Total Liabilities | 2.97M | 3.57M | 3.11M | 2.84M | 3.72M | 3.32M |
| Stockholders Equity | 3.75M | 5.70M | 13.63M | 29.46M | 35.59M | 56.39M |
Cash Flow | ||||||
| Free Cash Flow | -1.26M | -1.06M | -4.05M | -4.45M | -6.08M | -4.25M |
| Operating Cash Flow | -1.26M | -1.06M | -4.00M | -4.34M | -5.91M | -3.82M |
| Investing Cash Flow | 957.55K | 1.22M | -47.43K | 126.58K | -1.15M | -6.83M |
| Financing Cash Flow | -72.53K | -154.07K | -258.23K | -409.97K | -353.77K | -190.33K |
Ramm Pharma Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
8.17
Positive
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RAMM, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of <0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 8.17 is Positive, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RAMM.
Ramm Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | C$29.90M | -6.03 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$9.90M | -7.44 | -19.37% | ― | -19.20% | 42.54% | |
42 Neutral | C$53.62M | -0.76 | -2099.75% | ― | -100.00% | 94.43% | |
42 Neutral | C$1.19M | -0.13 | -194.41% | ― | -66.40% | 31.38% | |
41 Neutral | C$10.28M | -2.94 | 28.59% | ― | 0.90% | 57.73% | |
41 Neutral | C$13.44M | -3.09 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
TSE:RAMM
Ramm Pharma
0.01
0.00
0.00%
TSE:ATLE
Willow Biosciences Inc
0.12
-0.07
-37.84%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:PCLO
PharmaCielo
0.06
0.01
22.22%
TSE:AVCN
Avicanna
0.10
-0.17
-62.96%
TSE:INNO
InnoCan Pharma
2.20
-17.80
-89.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.